Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis
Arthritis Research and Therapy, Volume 15, No. 4, Article R91, Year 2013
Notification
URL copied to clipboard!
Description
Introduction: Our objective was to determine which one of the two function charts available in Spain to calculate cardiovascular (CV) risk, Systematic COronary Risk Evaluation (SCORE) or Framingham-REgistre GIroní del COR (REGICOR), should be used in patients with rheumatoid arthritis (RA).Methods: A series of RA patients seen over a one-year period without history of CV events were assessed. SCORE, REGICOR, modified (m)SCORE and mREGICOR according to the European League Against Rheumatism (EULAR) recommendations were applied. Carotid ultrasonography (US) was performed. Carotid intima-media thickness (cIMT) > 0.90 mm and/or carotid plaques were used as the gold standard test for severe subclinical atherosclerosis and high CV risk (US+). The area under the receiver operating curves (AUC) for the predicted risk for mSCORE and mREGICOR were calculated according to the presence of severe carotid US findings (US+).Results: We included 370 patients (80% women; mean age 58.9 ± 13.7 years); 36% had disease duration of 10 years or more; rheumatoid factor (RF) and/or anticyclic citrullinated peptide (anti-CCP) were positive in 68%; and 17% had extra-articular manifestations. The EULAR multiplier factor was used in 122 (33%) of the patients. The mSCORE was 2.16 ± 2.49% and the mREGICOR 4.36 ± 3.46%. Regarding US results, 196 (53%) patients were US+. The AUC mSCORE was 0.798 (CI 95%: 0.752 to 0.844) and AUC mREGICOR 0.741 (95% CI; 0.691 to 0.792). However, mSCORE and mREGICOR failed to identify 88% and 91% of US+ patients. More than 50% of patients with mSCORE ≥1% or mREGICOR >1% were US+.Conclusions: Neither of these two function charts was useful in estimating CV risk in Spanish RA patients. © 2013 Goméz-Vaquero et al.; licensee BioMed Central Ltd.
Authors & Co-Authors
Gómez-Vaquero, Carmen
Spain, Hospitalet de Llobregat
Institut D'investigació Biomedica de Bellvitge
Corrales, Alfonso F.
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Rueda-Gotor, Javier
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Blanco-Alonso, Ricardo
Spain, Santander
Hospital Universitario Marqués de Valdecilla
González-Juanatey, Carlos
Spain, Lugo
Hospital Lucus Augusti
Llorca-Díaz, Javier Francisco
Spain, Santander
Universidad de Cantabria
Spain, Madrid
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
González-Gay, Miguel Ángel
Spain, Santander
Hospital Universitario Marqués de Valdecilla
Statistics
Citations: 38
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1186/ar4271
ISSN:
14786362
Research Areas
Noncommunicable Diseases
Participants Gender
Female